Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 26, 2017 ) Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber the left ventricle is enlarged and weakened. Symptoms include Fatigue and weakness Shortness of breath (dyspnea) lightheadedness dizziness or fainting persistent cough or wheezing lack of appetite sudden weight gain from fluid retention and swelling (edema) in legs ankles and feet. Risk factors include family history alcoholism hypertension cocaine abuse and metabolic disorders such as thyroid disease or diabetes.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase II Phase I Preclinical Discovery and Unknown stages are 2 3 2 2 and 1 respectively. Similarly the Universities portfolio in Preclinical stages comprises 1 molecules respectively.
Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/dilated-cardiomyopathy-pipeline-review-h2-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular) . - The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881461/sample
Reasons to buy
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles Array BioPharma Inc Capricor Therapeutics Inc Hemostemix Ltd Kasiak Research Pvt Ltd MyoKardia Inc Sanofi
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881461/discount
List of Tables Number of Products under Development for Dilated Cardiomyopathy H2 2017 Number of Products under Development by Companies H2 2017 Number of Products under Development by Universities/Institutes H2 2017 Products under Development by Companies H2 2017 Products under Development by Universities/Institutes H2 2017 Number of Products by Stage and Target H2 2017 Number of Products by Stage and Mechanism of Action H2 2017 Number of Products by Stage and Route of Administration H2 2017 Number of Products by Stage and Molecule Type H2 2017 Dilated Cardiomyopathy-Pipeline by Array BioPharma Inc H2 2017 Dilated Cardiomyopathy-Pipeline by Capricor Therapeutics Inc H2 2017 Dilated Cardiomyopathy-Pipeline by Hemostemix Ltd H2 2017 Dilated Cardiomyopathy-Pipeline by Kasiak Research Pvt Ltd H2 2017 Dilated Cardiomyopathy-Pipeline by MyoKardia Inc H2 2017 Dilated Cardiomyopathy-Pipeline by Sanofi H2 2017 Dilated Cardiomyopathy-Pipeline by Vericel Corp H2 2017 Dilated Cardiomyopathy-Dormant Projects H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881461/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
Source: EmailWire.com
|
|
|
|